Navinci Diagnostics, a Sweden-based life science company, raised SEK 90M in Series A funding.
The round was led by Segulah Medical Acceleration with participation from Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.
The company intends to use the funds to accelerate international commercialization and partner with pharma companies, as well as companies with complementary technologies, to offer complete solutions for its customers.
Led by CEO Robert Gunnarsson, Navinci (formerly known as Olink Bioscience) is a life science company that develops and markets in situ proximity ligation assays to detect proteins, their interactions, and modifications in tissue and cell samples, with initial focus on immuno-oncology research and drug development.
The company will soon launch the first commercially available assay to accurately detect interaction between the programmed cell death protein 1 (PD1) and PD1-ligand (PD-L1) checkpoint in tissue samples.
FinSMEs
12/07/2022